Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers
Sponsor: Enanta Pharmaceuticals, Inc
A PHASE1 clinical study on NASH - Nonalcoholic Steatohepatitis, this trial is completed. The trial is conducted by Enanta Pharmaceuticals, Inc and has accumulated 7 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Nov 2022 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Aug 2017 — Dec 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Enanta Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .